Related Experiment Video
Updated: Feb 8, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Mitoxantrone induces apoptosis in osteosarcoma cells through regulation of the Akt/FOXO3 pathway
See-Hyoung Park1, Jongsung Lee2, Mi-Ae Kang3
1Department of Bio and Chemical Engineering, Hongik University, Sejong, Chungcheong 30016, Republic of Korea.
Abstract:
The outcome of chemotherapy for osteosarcoma have improved during the past decade and more patients have access to combination chemotherapy, but there has been no significant clinical progress in the patient survival rate. Recently, forkhead-box O3 (FOXO3) was identified as a pivotal transcription factor responsible for the transcriptional regulation of genes associated with suppression of cancer. The purpose of the present study was to screen small chemicals activating FOXO3 and elucidate their underlying mechanism. Using a drug discovery platform based on the phosphorylation status of FOXO3 in osteosarcoma cells, mitoxantrone (MTZ), a type of DNA-damaging agent, was selected as a possible FOXO3 activator from the food and drug administration-approved drug library. MTZ treatments significantly inhibited the phosphorylation level of Akt-pS473 and caused nuclear localization of FOXO3 in osteosarcoma cells. MTZ treatment inhibited proliferation in osteosarcoma cells in vitro, whereas silencing FOXO3 potently attenuates MTZ-mediated apoptosis in osteosarcoma cells. Taken together, the results indicated that MTZ induces apoptosis in osteosarcoma cells through an Akt/FOXO3-dependent mechanism.
Insights
Mitoxantrone activates the FOXO3 protein in osteosarcoma cells, inhibiting cancer growth. This DNA-damaging agent induces cancer cell death via an Akt/FOXO3 pathway, offering a potential new treatment strategy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Osteosarcoma chemotherapy has improved, but patient survival rates remain stagnant.
- Forkhead-box O3 (FOXO3) is a key transcription factor in cancer suppression.
- Identifying FOXO3 activators could lead to novel cancer therapies.
Purpose of the Study:
- To screen for small molecules that activate FOXO3.
- To elucidate the mechanism of FOXO3 activation in osteosarcoma.
- To evaluate the therapeutic potential of FOXO3 activators.
Main Methods:
- Utilized a drug discovery platform measuring FOXO3 phosphorylation in osteosarcoma cells.
- Screened the FDA-approved drug library for FOXO3 activators.
- Investigated the effect of mitoxantrone (MTZ) on Akt phosphorylation and FOXO3 localization.
- Assessed MTZ's impact on osteosarcoma cell proliferation and apoptosis, with and without FOXO3 silencing.
Main Results:
- Mitoxantrone (MTZ), a DNA-damaging agent, was identified as a FOXO3 activator.
- MTZ treatment decreased Akt phosphorylation (Akt-pS473) and promoted FOXO3 nuclear localization in osteosarcoma cells.
- MTZ inhibited osteosarcoma cell proliferation in vitro.
- Silencing FOXO3 significantly reduced MTZ-induced apoptosis in osteosarcoma cells.
Conclusions:
- Mitoxantrone induces apoptosis in osteosarcoma cells.
- The mechanism involves the Akt/FOXO3 pathway.
- MTZ shows promise as a therapeutic agent for osteosarcoma by activating FOXO3.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Apoptosis
GTPases and their Regulation
Large G-proteins,...
Negative Regulator Molecules
pH Regulation in Cells
Cytosolic pH
Under physiological conditions, the cytosolic pH is slightly more acidic than the extracellular pH. However, cells must prevent further acidification of their cytosol to...
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....

